Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -31.37% is 56% above its 5-year average of -71.17%, near the high end of its 5-year range (-220.85%–-6.84%).
18.90% below its 12-month average of -26.38%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -20.06%.
OPERATING MARGIN
-31.37%
OPERATING MARGIN AVG TTM
-26.38%
OPERATING MARGIN AVG 3Y
-40.20%
OPERATING MARGIN AVG 5Y
-71.17%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-18.90%
CURRENT VS 3Y AVG
+21.97%
CURRENT VS 5Y AVG
+55.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 389 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Biodesix, Inc.
Market Cap
$236.56M
Operating Margin
-31.37%
TTM Avg
-26.38%
3Y Avg
-40.20%
5Y Avg
-71.17%
Market Cap
$239.45M
Operating Margin
-1026.28%
TTM Avg
-515.73%
3Y Avg
-257.87%
5Y Avg
-257.87%
Market Cap
$244.25M
Operating Margin
9.95%
TTM Avg
-10.78%
3Y Avg
-18.24%
5Y Avg
-54.36%
Market Cap
$245.65M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$248.21M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$251.64M
Operating Margin
-1488.31%
TTM Avg
-4815.32%
3Y Avg
-6115.40%
5Y Avg
-4078.06%
Market Cap
$220.94M
Operating Margin
-692.83%
TTM Avg
-418.51%
3Y Avg
-274.13%
5Y Avg
-339.94%
Market Cap
$218.42M
Operating Margin
40.94%
TTM Avg
-5.20%
3Y Avg
-130.22%
5Y Avg
-446.71%
Market Cap
$259.30M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biodesix, Inc. (BDSX) | $236.56M | -31.37% | -26.38% | -40.20% | -71.17% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -1026.28% | -515.73% | -257.87% | -257.87% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 9.95% | -10.78% | -18.24% | -54.36% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | -1488.31% | -4815.32% | -6115.40% | -4078.06% |
| Alector, Inc. (ALEC)vs › | $220.94M | -692.83% | -418.51% | -274.13% | -339.94% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 40.94% | -5.20% | -130.22% | -446.71% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | -4.24% | -7.03% | -2.53% | -5.01% |
Gross Margin
82.5%
Operating Margin
-31.4%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -20.06% |
| 2026-03-31 | -24.25% |
| 2025-12-31 | -6.84% |
| 2025-09-30 | -32.36% |
| 2025-06-30 | -48.42% |
| 2025-03-31 | -50.47% |
| 2024-12-31 | -32.55% |
| 2024-09-30 | -47.33% |
| 2024-06-30 | -45.95% |
| 2024-03-31 | -74.38% |
| 2023-12-31 | -46.67% |
| 2023-09-30 | -53.16% |
| 2023-06-30 | -92.04% |
| 2023-03-31 | -180.80% |
| 2022-12-31 | -144.58% |
| 2022-09-30 | -95.53% |
| 2022-06-30 | -106.17% |
| 2022-03-31 | -220.85% |
| 2021-12-31 | -161.67% |
| 2021-09-30 | -200.44% |
| 2021-06-30 | -89.08% |
| 2021-03-31 | -19.34% |
| 2020-12-31 | -9.82% |
| 2020-09-30 | -67.88% |
| 2020-06-30 | -132.55% |
| 2020-03-31 | -165.27% |
| 2019-12-31 | -42.85% |
| 2019-09-30 | -229.02% |
| 2019-06-30 | -96.26% |
| 2019-03-31 | -96.26% |
| 2018-06-30 | -88.40% |
| 2018-03-31 | -88.40% |
